NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis.

Date Issued
2019
Author(s)
Uhl, Waldemar
Ettrich, Thomas Jens
Reinacher-Schick, Anke C.
Algül, Hana
Friess, Helmut
Kornmann, Marko
Wittel, Uwe A
Gallmeier, Eike
Wille, Kai
Geissler, Michael
Schimanski, Carl Christoph
Prasnikar, Nicole
Tannapfel, Andrea
Perkhofer, Lukas
Berger, Andreas W.
Seufferlein, Thomas
DOI
10.1200/JCO.2019.37.15_suppl.4128